Back

One-year effectiveness and safety outcomes of edoxaban treatment in Chinese patients with atrial fibrillation: First snapshot of more than 4,800 patients from the ETNA-AF-China study

7 April 2024 (08:30 - 15:00)
Organised by: Logo
Congress Presentation Part of: Poster session on devices, others Stroke in Atrial Fibrillation EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Martin Unverdorben

Daiichi Sankyo, Inc., Basking Ridge, NJ (United States of America)

108 More presentations in this session

Presentation thumbnail
Emergency leadless pacing implantation is feasible and safe out-of-hours
Doctor F. O'Rourke (London, GB)
Abstract Slides Video
Presentation thumbnail
Outcomes of subcutaneous implantable cardioverter defibrillators: UK tertiary centre experience
Doctor L. Toon (Southampton, GB)
Abstract Slides Video
Presentation thumbnail
Evaluation of the quality of life of patients with leadless pacing system during 1 year follow-up period
Doctor A. Baimbetov (Almaty, KZ)
Abstract Slides
Presentation thumbnail
Which paced QRS duration can be achieved in selective and non-selective His bundle pacing?
Mr C. Israel (Bielefeld, DE)
Abstract Slides Video
Presentation thumbnail
Procedural heart rate variability and its effect on short-term symptoms after cardioneuromodulation procedure
Doctor S. AYGUN (Ankara, TR)
Abstract

Access the full session

Session thumbnail
Poster session on devices, others

The Event

Event poster

EHRA 2024

7 April - 9 April 2024
You may be interested in
thumbnail
Congress Presentation
Clinical outcomes of edoxaban treatment in atrial fibrillation patients with high bleeding risk: insights from the ETNA-AF-China 1-year follow-up
thumbnail
Congress Presentation
Low rates of haemorrhagic stroke, not increased by age, renal/hepatic impairment, concomitant anti-platelet use and high CHA2DS2-VASc scores, in the 4-year follow-up of ETNA-AF-Europe
thumbnail
Congress Presentation
Clinical outcomes in >10,000 Asian vs >61,000 Non-Asian race patients with AF randomized to Warfarin vs DOACs: a patient-level meta-analyses from COMBINE AF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources